Why Danaher Corporation (DHR) stock moved
Danaher Corporation (DHR) shares fell 2.3% to $231.59 as of October 30, 2026, a modest decline from the prior close of $236.98. BestStocks flagged the session as a major change for DHR. The move is tied to a new SEC filing. Below, we break down what changed for DHR, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
SEC Filing
Danaher Corporation (DHR) filed a new 10-Q on 2026-10-21. DHR earnings scheduled for 2027-01-27 (date not yet confirmed), with consensus EPS estimate of $2.57.
What it means for Danaher Corporation investors
For Danaher Corporation investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Earnings beat — stock sold off (sell-the-news reaction); Positive price momentum. Weighing against that: Negative session, down 2.3%; New SEC filing — review for material disclosures. Because the move outpaced peers, it looks driven by DHR-specific developments rather than a broad sector rotation. Wall Street's consensus price target sits at $238.77, implying +3.1% upside from $231.59. BestStocks rates the overall signal quality low (48/100). With earnings roughly 89 days out, the next report is the most likely near-term test of the move.
DHR price reaction
DHR last traded at $231.59, down $5.39 (-2.27%) from the previous close of $236.98. The session traded on 0.4× average volume (below avg), so participation was unremarkable. Its healthcare peer group moved a median +1.9% over the same stretch, leaving DHR behind the group by 4.1 points. Over the past month the stock has ranged between $211.76 and $236.98, and it currently sits about 79% of the way up that band.
Bullish and bearish analyst opinions on Danaher Corporation (DHR)
The consensus analyst price target on Danaher Corporation (DHR) is $238.77, 3.1% above the recent $231.59. Over the past 90 days analysts logged 0 upgrades, 11 maintains, and 0 downgrades. Here is how the bullish and bearish cases on DHR line up.
The bullish case
- Wall Street's consensus price target of $238.77 implies +3.1% upside from $231.59.
- The Street's most bullish target is $275.00 (+18.7%).
- Earnings beat — stock sold off (sell-the-news reaction).
- Positive price momentum.
The bearish case
- The most bearish analyst target is $195.00 (-15.8%).
- Negative session, down 2.3%.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 30, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for DHR
Frequently asked questions about DHR
Why did Danaher Corporation (DHR) stock move?
DHR fell 2.3% to $231.59. The move is associated with a new SEC filing and looks like a company-specific move.
How much did DHR stock fall?
DHR lost 2.27% ($5.39) versus the prior close of $236.98, last trading at $231.59 on 0.4× average volume.
When is Danaher Corporation's next earnings date?
DHR's next earnings report is estimated for 2027-01-27 — about 89 days away.
What is the analyst price target for DHR?
The consensus analyst price target for DHR is $238.77, about 3.1% above the current $231.59. Over the past 90 days, analysts recorded 0 upgrades, 11 maintains, and 0 downgrades.
Is the DHR move company-specific or sector-wide?
BestStocks classifies it as a company-specific move: the peer group moved a median +1.9% against DHR's -2.3%. DHR ranks top 7 of 7 peers.
How BestStocks tracks DHR
This page is generated automatically by BestStocks' change-detection system after a new SEC filing was detected and verified against independent data sources. It draws on 20 tracked change events for DHR, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 30, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
